Explore ›
Finding
Finding
null
Combination therapy with fenofibrate and simvastatin was not associated with increased risk of myopathy compared with simvastatin alone, with muscle symptom rates of 40.1% vs 40.5% (p=0.79), elevated CPK rates of 0.3% in both groups, and myositis/rhabdomyolysis rates of 0.1% in both groups.
| Effect size | 40.1% vs 40.5% |
| Follow-up | 4.7 years |
| Comparator | Placebo added to simvastatin (20-40 mg/day) |
| Effect summary | null; 40.1% vs 40.5% |
| Adverse events | muscle symptoms 40.1% vs 40.5%, elevated CPK 0.3%, myositis/rhabdomyolysis 0.1% |
Connected entities
Interventions
Conditions
Outcomes
Source
PMC4509601
The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus